Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $611,250.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer directly owned 42,181 shares in the company, valued at $5,156,627.25. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.82, for a total value of $469,100.00.

Mirum Pharmaceuticals Price Performance

MIRM stock traded up $0.26 during midday trading on Wednesday, reaching $128.57. 885,134 shares of the company’s stock traded hands, compared to its average volume of 931,937. The company has a 50-day simple moving average of $104.54 and a two-hundred day simple moving average of $96.79. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $129.00. The company has a market cap of $7.84 billion, a price-to-earnings ratio of -9.45 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) EPS. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after purchasing an additional 1,067,722 shares during the period. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares during the period. Wellington Management Group LLP grew its position in shares of Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after buying an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after buying an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its stake in shares of Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have commented on MIRM shares. Wolfe Research initiated coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price objective on the stock. CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Evercore reissued an “outperform” rating and set a $138.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. HC Wainwright reissued a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Wall Street Zen cut shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $143.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.